{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T17:49:21Z","timestamp":1779299361148,"version":"3.51.4"},"reference-count":41,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1124\/jpet.119.260653","type":"journal-article","created":{"date-parts":[[2019,10,19]],"date-time":"2019-10-19T00:58:21Z","timestamp":1571446701000},"page":"21-29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["The Novel CYP2A6 Inhibitor, DLCI-1, Decreases Nicotine Self-Administration in Mice"],"prefix":"10.1016","volume":"372","author":[{"given":"Yen-Chu","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James P.","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christy J.W.","family":"Watson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasmine","family":"Sherafat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andres","family":"Staben","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Lazarus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Travis T.","family":"Denton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2864-2163","authenticated-orcid":false,"given":"Christie D.","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.119.260653_bib1","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1749-6632.1995.tb17464.x","article-title":"Nicotinic receptor function in the mammalian central nervous system","volume":"757","author":"Albuquerque","year":"1995","journal-title":"Ann N Y Acad Sci"},{"key":"10.1124\/jpet.119.260653_bib2","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/ntr\/ntt105","article-title":"Pharmacokinetic and pharmacodynamics studies of nicotine after oral administration in mice: effects of methoxsalen, a CYP2A5\/6 inhibitor","volume":"16","author":"Alsharari","year":"2014","journal-title":"Nicotine Tob Res"},{"key":"10.1124\/jpet.119.260653_bib3","first-page":"890","article-title":"Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers","volume":"11","author":"Ariyoshi","year":"2002","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1124\/jpet.119.260653_bib4","doi-asserted-by":"crossref","first-page":"e264","DOI":"10.1542\/peds.2006-1583","article-title":"The role of CYP2A6 in the emergence of nicotine dependence in adolescents","volume":"119","author":"Audrain-McGovern","year":"2007","journal-title":"Pediatrics"},{"key":"10.1124\/jpet.119.260653_bib5","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.neuropharm.2014.05.006","article-title":"Effects of methoxsalen, a CYP2A5\/6 inhibitor, on nicotine dependence behaviors in mice","volume":"85","author":"Bagdas","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.119.260653_bib6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/978-3-540-69248-5_2","article-title":"Nicotine chemistry, metabolism, kinetics and biomarkers","volume":"192","author":"Benowitz","year":"2009","journal-title":"Handb Exp Pharmacol"},{"key":"10.1124\/jpet.119.260653_bib7","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/clpt.1994.169","article-title":"Metabolism of nicotine to cotinine studied by a dual stable isotope method","volume":"56","author":"Benowitz","year":"1994","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.119.260653_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/dmd.105.004747","article-title":"Mechanism-based inactivation and reversibility: is there a new trend in the inactivation of cytochrome p450 enzymes?","volume":"34","author":"Blobaum","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.119.260653_bib9","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/FPC.0b013e328346e8c0","article-title":"The contribution of common CYP2A6 alleles to variation in nicotine metabolism among European-Americans","volume":"21","author":"Bloom","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"10.1124\/jpet.119.260653_bib10","first-page":"1226","article-title":"Smoking-attributable mortality, years of potential life lost, and productivity losses--United States, 2000-2004","volume":"57","year":"2008","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1124\/jpet.119.260653_bib11","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.drugalcdep.2018.06.003","article-title":"Nicotine metabolite ratio predicts smoking topography: the Pennsylvania Adult Smoking Study","volume":"190","author":"Chen","year":"2018","journal-title":"Drug Alcohol Depend"},{"key":"10.1124\/jpet.119.260653_bib12","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1523\/JNEUROSCI.1433-17.2018","article-title":"Altered baseline and nicotine-mediated behavioral and cholinergic profiles in ChAT-Cre mouse lines","volume":"38","author":"Chen","year":"2018","journal-title":"J Neurosci"},{"key":"10.1124\/jpet.119.260653_bib13","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1124\/jpet.110.166850","article-title":"Effects of hydroxymetabolites of bupropion on nicotine dependence behavior in mice","volume":"334","author":"Damaj","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.119.260653_bib14","doi-asserted-by":"crossref","first-page":"7065","DOI":"10.1021\/acs.jmedchem.8b00084","article-title":"Identification of the 4-position of 3-alkynyl and 3-heteroaromatic substituted pyridine methanamines as a key modification site eliciting increased potency and enhanced selectivity for cytochrome P-450 2A6 inhibition","volume":"61","author":"Denton","year":"2018","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.119.260653_bib15","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.addbeh.2013.10.028","article-title":"A longitudinal study of electronic cigarette users","volume":"39","author":"Etter","year":"2014","journal-title":"Addict Behav"},{"key":"10.1124\/jpet.119.260653_bib16","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.neuropharm.2011.05.012","article-title":"Intravenous nicotine self-administration and cue-induced reinstatement in mice: effects of nicotine dose, rate of drug infusion and prior instrumental training","volume":"61","author":"Fowler","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.119.260653_bib17","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.neuropharm.2013.09.008","article-title":"Nicotine aversion: neurobiological mechanisms and relevance to tobacco dependence vulnerability","volume":"76","author":"Fowler","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.119.260653_bib18","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nature09797","article-title":"Habenular \u03b15 nicotinic receptor subunit signalling controls nicotine intake","volume":"471","author":"Fowler","year":"2011","journal-title":"Nature"},{"key":"10.1124\/jpet.119.260653_bib19","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/S0140-6736(17)30819-X","article-title":"Smoking prevalence and attributable disease burden in 195 countries and territories, 1990-2015: a systematic analysis from the Global Burden of Disease Study 2015 [published correction appears in Lancet (2017) 390:1644]","volume":"389","year":"2017","journal-title":"Lancet"},{"key":"10.1124\/jpet.119.260653_bib20","doi-asserted-by":"crossref","first-page":"h3317","DOI":"10.1136\/bmj.h3317","article-title":"Why e-cigarettes are dividing the public health community","volume":"350","author":"Gornall","year":"2015","journal-title":"BMJ"},{"key":"10.1124\/jpet.119.260653_bib21","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1093\/ntr\/nts088","article-title":"Bupropion and its main metabolite reverse nicotine chronic tolerance in the mouse","volume":"14","author":"Grabus","year":"2012","journal-title":"Nicotine Tob Res"},{"key":"10.1124\/jpet.119.260653_bib22","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.pbb.2015.01.009","article-title":"Bupropion-varenicline interactions and nicotine self-administration behavior in rats","volume":"130","author":"Hall","year":"2015","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/jpet.119.260653_bib23","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0928-4257(98)80140-X","article-title":"Allosteric nicotinic receptors, human pathologies","volume":"92","author":"L\u00e9na","year":"1998","journal-title":"J Physiol Paris"},{"key":"10.1124\/jpet.119.260653_bib24","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/cpt.1238","article-title":"Effects of nicotine metabolic rate on withdrawal symptoms and response to cigarette smoking after abstinence","volume":"105","author":"Liakoni","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.119.260653_bib25","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00213-006-0441-0","article-title":"Guidelines on nicotine dose selection for in vivo research","volume":"190","author":"Matta","year":"2007","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.119.260653_bib26","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/sj.clpt.6100246","article-title":"Identification of novel CYP2A6*1B variants: the CYP2A6*1B allele is associated with faster in vivo nicotine metabolism","volume":"83","author":"Mwenifumbo","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.119.260653_bib27","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/clpt.2008.57","article-title":"Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion","volume":"84","author":"Patterson","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.119.260653_bib28","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1001\/jamapediatrics.2015.1742","article-title":"Progression to traditional cigarette smoking after electronic cigarette use among US adolescents and young adults","volume":"169","author":"Primack","year":"2015","journal-title":"JAMA Pediatr"},{"key":"10.1124\/jpet.119.260653_bib29","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.pbb.2008.05.002","article-title":"Bupropion differentially alters the aversive, locomotor and rewarding properties of nicotine in CD-1 mice","volume":"90","author":"Rauhut","year":"2008","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/jpet.119.260653_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00213-003-1450-x","article-title":"Effect of bupropion on nicotine self-administration in rats","volume":"169","author":"Rauhut","year":"2003","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.119.260653_bib31","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1515\/dmdi-2012-0001","article-title":"CYP2A6: genetics, structure, regulation, and function","volume":"27","author":"Raunio","year":"2012","journal-title":"Drug Metabol Drug Interact"},{"key":"10.1124\/jpet.119.260653_bib32","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1080\/01677060802572887","article-title":"Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymes","volume":"23","author":"Ray","year":"2009","journal-title":"J Neurogenet"},{"key":"10.1124\/jpet.119.260653_bib33","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1177\/0269881111405352","article-title":"Combined analysis of CHRNA5, CHRNA3 and CYP2A6 in relation to adolescent smoking behaviour","volume":"25","author":"Rodriguez","year":"2011","journal-title":"J Psychopharmacol"},{"key":"10.1124\/jpet.119.260653_bib34","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1067\/mcp.2000.107651","article-title":"Inhibition of cytochrome P450 2A6 increases nicotine\u2019s oral bioavailability and decreases smoking","volume":"68","author":"Sellers","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.119.260653_bib35","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1503\/cmaj.131534","article-title":"Bupropion abuse and overdose","volume":"186","author":"Stall","year":"2014","journal-title":"CMAJ"},{"key":"10.1124\/jpet.119.260653_bib36","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1158\/1055-9965.EPI-10-0674","article-title":"Nicotine metabolite ratio predicts smoking topography and carcinogen biomarker level","volume":"20","author":"Strasser","year":"2011","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1124\/jpet.119.260653_bib37","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1080\/14622200701239605","article-title":"An association of CYP2A6 genotype and smoking topography","volume":"9","author":"Strasser","year":"2007","journal-title":"Nicotine Tob Res"},{"key":"10.1124\/jpet.119.260653_bib38","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/ng.573","article-title":"Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior","volume":"42","author":"Thorgeirsson","year":"2010","journal-title":"Nat Genet"},{"key":"10.1124\/jpet.119.260653_bib39","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.bcp.2011.06.026","article-title":"Recent advances in understanding nicotinic receptor signaling mechanisms that regulate drug self-administration behavior","volume":"82","author":"Tuesta","year":"2011","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/jpet.119.260653_bib40","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1124\/jpet.112.195255","article-title":"CYP2A6- and CYP2A13-catalyzed metabolism of the nicotine \u03945\u2018(1\u2019)iminium ion","volume":"343","author":"von Weymarn","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.119.260653_bib41","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1093\/jnci\/djr237","article-title":"Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk","volume":"103","author":"Wassenaar","year":"2011","journal-title":"J Natl Cancer Inst"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524269469?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524269469?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.119.260653","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T11:21:35Z","timestamp":1749813695000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524269469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0022356524269469"],"URL":"https:\/\/doi.org\/10.1124\/jpet.119.260653","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Novel CYP2A6 Inhibitor, DLCI-1, Decreases Nicotine Self-Administration in Mice","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.119.260653","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}